Please use a PC Browser to access Register-Tadawul
Get It
Stock Ratings | Potential Upside of 378.93%! Wells Fargo raised its price target on Atter Pharma to $25 and maintained its Overweight rating.
aTyr Pharma, Inc. - Common Stock -0.56%
Array Technologies -2.23%
Liberty Media Corp. Series C Liberty Braves +0.50%
Metsera, Inc. +7.88%
Cocrystal Pharma, Inc. +14.65%
aTyr Pharma, Inc. - Common Stock ATYR | 5.30 | -0.56% |
Array Technologies ARRY | 7.47 | -2.23% |
Liberty Media Corp. Series C Liberty Braves BATRK | 46.60 | +0.50% |
Metsera, Inc. MTSR | 39.28 | +7.88% |
Cocrystal Pharma, Inc. COCP | 1.80 | +14.65% |
Major US investment bank ratings are used to track the latest valuations and target prices on Wall Street daily, and to explore potential stock investment opportunities.
Hazard Warning:
Investing in small-cap stocks can be risky. Be prepared for potential liquidity challenges, high volatility, limited information, and financial instability. Always diversify your investments.
Today's Key Ratings and Concerns
Wells Fargo: Maintained an "Overweight" rating on aTyr Pharma ( aTyr Pharma, Inc. - Common Stock(ATYR.US) ), raising the price target from $17 to $25.
JP Morgan: Maintained an “Overweight” rating on Array Technologies(ARRY.US) ), raising the price target from $12 to $13.
Rosenblatt: Maintained a "Buy" rating on Atlanta Braves Holdings ( Liberty Media Corp. Series C Liberty Braves(BATRK.US) ), raising the price target from $52 to $69.
Wells Fargo: Initial rating for Metsera, Inc.(MTSR.US) ) with an "Overweight" recommendation and a $65 price target.
HC Wainwright & Co.: Maintains a "Buy" rating on Cocrystal Pharma, Inc.(COCP.US) ), lowering the price target from $7 to $6.
| The symbol | Classification | Target price | Current price | Potential increase/decrease rate | (Classification) Agency |
| aTyr Pharma, Inc. - Common Stock(ATYR.US) | to lift | $25.0 | $5.22 | 378.93% | Wells Fargo |
| Array Technologies(ARRY.US) | to lift | $13.0 | $7.4 | 75.68% | JP Morgan |
| Liberty Media Corp. Series C Liberty Braves(BATRK.US) | to lift | $69.0 | $45.99 | 50.03% | Rosenblatt |
| Onity Group Inc. Ordinary Shares(ONIT.US) | to lift | $55.0 | $37.44 | 46.9% | B. Riley Securities |
| Cameco Corporation(CCJ.US) | to lift | $100.0 | $68.27 | 46.48% | RBC Capital |
| Metsera, Inc.(MTSR.US) | Initial classification | $65.0 | $29.6 | 119.59% | Wells Fargo |
| Cocrystal Pharma, Inc.(COCP.US) | cut | $6.0 | $1.49 | 302.68% | HC Wainwright & Co. |
| Sarepta Therapeutics, Inc.(SRPT.US) | cut | $45.0 | $20.08 | 124.1% | Oppenheimer |
| ADC Therapeutics SA(ADCT.US) | cut | $5.0 | $2.77 | 80.51% | RBC Capital |
| Winnebago Industries, Inc.(WGO.US) | cut | $50.0 | $31.19 | 60.31% | BMO Capital |
comments:
Target price unit and current price: US dollar;
Current Price: As of the latest closing price of US stocks;
Potential increase/decrease ratio = (Agency target price - current price) / current price 100% (Current price = last closing price up to the time of census)
Lifting
Oppenheimer: Maintained Amazon.com ( Amazon.com, Inc.(AMZN.US) rating of "Outperform," raising the price target from $215 to $250.
Wells Fargo: Maintained Array Technologies(ARRY.US) ) rating at "market-weight," raising the price target from $7 to $8.
Wells Fargo: Maintained an "Overweight" rating on aTyr Pharma ( aTyr Pharma, Inc. - Common Stock(ATYR.US) ), raising the price target from $17 to $25.
Barclays: Maintained an “Overweight” rating on Couchbase, Inc.(BASE.US) ), raising the price target from $22 to $24.5.
Rosenblatt: Maintained a "Buy" rating on Atlanta Braves Holdings ( Liberty Media Corp. Series C Liberty Braves(BATRK.US) ), raising the price target from $52 to $69.
RBC Capital: Maintained Cameco Corp. ( Cameco Corporation(CCJ.US) ) rating at “Outperform,” raising the price target from $90 to $100.
Morgan Stanley: Maintained a “market-weight” rating for Cleveland Cliffs Natural Resources Inc.(CLF.US) ), raising the price target from $7.5 to $8.
Morgan Stanley: Maintained Commercial Metals Company(CMC.US) )'s "Market-Weight" rating, raising the price target from $48 to $53.
First coverage
Roth Capital: Initial rating for Adeia ( Xperi Holding Corp(ADEA.US) ) with a "Buy" recommendation and a $26 price target.
Seaport Global: Initial rating for Circle Internet Group ( Circle(CRCL.US) ) with a "Buy" recommendation and a $235 price target.
B of A Securities: Initial rating for Kinsale Cap Gr ( Kinsale Capital Group, Inc.(KNSL.US) ) is "Buy", with a target price of $543.
Wells Fargo: Initial rating for Metsera Metsera, Inc.(MTSR.US) ) with an "Overweight" recommendation and a $65 price target.
Wedbush: Initial rating for NCR Atleos ( NCR Atleos, LLC(NATL.US) ) at "Outperform", with a $35 price target.
CICC: Initial rating for Snowflake ( Snowflake(SNOW.US) ) with an "Outperform" recommendation, with a $225 price target.
Macquarie: Initial rating for Sportradar Gr ( Sportradar Group AG(SRAD.US) ) is "Outperform", with a price target of $32.
reduction
RBC Capital: Maintains ADC Therapeutics ( ADC Therapeutics SA(ADCT.US) ) “Outperform” rating, lowers price target from $8 to $5.
Needham: Downgraded Couchbase ( Couchbase, Inc.(BASE.US) ) to "Hold," maintaining the price target at $22.
Wells Fargo: Downgraded Couchbase ( Couchbase, Inc.(BASE.US) ) to "Market Weight," raising the price target from $20 to $24.5.
Wedbush: Maintained Builders Builders FirstSource, Inc.(BLDR.US) “Outperform” rating, lowered price target to $145 from $190.
HC Wainwright & Co.: Maintains a "Buy" rating on Cocrystal Pharma, Inc.(COCP.US) ), lowering the price target from $7 to $6.
Editor's Note: This content was generated by Sahm's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risks, and securities prices may rise, fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance does not necessarily reflect future performance. Before making any investment decision, investors should evaluate their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and the risks associated with them. For further details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, you are advised to seek independent professional advice.
